Genmab — Maj 2020
-
Er med på, at en Partneraftale kan indeholde mange elementer, som kan påvirke om den er god eller dårlig, men overordnet er forventningen vel 50/50, og med et positivt udgangspunkt for GEN, incl. ukendte elementer. Så forventningen er vel en stigning, eller minimum status quo? JW har jo været klar i sine forventninger / udmeldinger til en aftale.
-
Ja det er super vigtigt, da Genmab præklinik jo hovedsageligt bygges på BsAbs - det er jo hele deres fremtid som får en kraftig vallidering i disse tider. Både af Janssen men også Genmab selv, hvilket jo giver os en fin indikation af, at platformen ikke fejler noget og Genmabs egne evner ikke fejler noget.
-
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody
Platform against a Pair of Disease Relevant Targets https://www.prnewswire.com/news-releases/tavotek-announces-a-research-agreement-with-genmab-for-the-development-of-bispecific-antibodies-using-genmabs-duobody-platform-against-a-pair-of-disease-relevant-targets-301064163.html -
UBS increase target on Genmab to 2500 from 1460, and view to buy from neutral

-
Er du da svedt.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind